<DOC>
	<DOCNO>NCT02411162</DOCNO>
	<brief_summary>This open-label , non-randomized , single-center study ass residency GSK2894512 skin healthy adult male volunteer normal barrier function . The study two part , Cohort 1 ( Part A ) follow Cohort 2 ( Part B ) . The study assess residence time human skin . The primary objective evaluate residency time skin follow topical application two formulation GSK2894512 Cream . The total study duration 15 day include 1 7 day treatment period , 8 14 day post treatment period 1 day follow . The screening period 28 day prior Baseline ( Day 1 ) .</brief_summary>
	<brief_title>A Single Dose Phase I Exploratory Study Healthy Volunteers With GSK2894512 Cream</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Males , 18 45 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Skin tone potential test site forearm erythema dermal reaction easily visualize , i.e . Fitzpatrick skin type I ( always burn ; never tan ) , II ( usually burn ; tan difficulty ) , III ( sometimes mild burn ; gradually tan ) , IV ( rarely burn ; tan ease ) include . Determination skin type base sunburn tan history response first 30 45 minute sun exposure . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator , consultation Medical Monitor , agree document find unlikely introduce additional risk factor interfere study procedure . Subjects value outside normal range always exclude enrolment . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Corrected QT interval ( QTc ) &gt; 450 millisecond ( msec ) Concurrent condition history disease : Immunocompromized ( eg , lymphoma , acquire immune deficiency syndrome ( AIDS ) , WiskottAldrich Syndrome history malignant disease within 5 year baseline visit , exception basal squamous cell cancer ; Active acute bacterial , fungal viral skin infection ( e.g. , herpes simplex , herpes zoster , chicken pox ) ; Any concomitant skin disorder ( e.g. , generalized erythroderma Netherton 's Syndrome , atopic dermatitis psoriasis ) , pigmentation , extensive scar opinion investigator may interfere test site evaluation contraindicate participation ; clinical sign infection ( viral , fungal bacterial ) within treatment area ; type skin disease may impact evaluation . Inability evaluate skin around potential test site forearm due sunburn , unevenness skin tone , tattoo , scar , excessive hair , freckle , birthmark , mole , skin damage abnormality . Chronic acute infection require treatment systemic antibiotic , antiviral , antiparasitics , antiprotozoal , antifungal within 4 week baseline visit , superficial skin infection within 1 week screen visit . Planning significant exposure ultraviolet ( UV ) radiation ( sunbathe tan ) . Planning use sauna duration study intend swim week . Participation clinical drug device research study within previous 30 day . History sensitivity study medication , local anesthesia , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Concomitant Medications : Investigational product topical medication product ( include limit selftanning product , wax product , benzoyl peroxide , salicylic acid , sulphur ) area test . Contraindications : History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . . For potent immunosuppressive agent , subject presence hepatitis B core antibody ( HBcAb ) also exclude . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>FLIM</keyword>
	<keyword>chronic plaque psoriasis</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>GSK2894512</keyword>
	<keyword>Skin residency</keyword>
</DOC>